Nuvectis Pharma (NASDAQ:NVCT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Nuvectis Pharma (NASDAQ:NVCT) from a sell rating to a hold rating in a research note published on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

Nuvectis Pharma Stock Performance

NVCT opened at $11.65 on Friday. Nuvectis Pharma has a fifty-two week low of $5.55 and a fifty-two week high of $11.74. The company has a fifty day moving average of $8.56 and a two-hundred day moving average of $7.84. The stock has a market capitalization of $309.03 million, a price-to-earnings ratio of -8.89 and a beta of -0.11.

Nuvectis Pharma (NASDAQ:NVCT) last released its earnings results on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. On average, equities research analysts forecast that Nuvectis Pharma will post -1.01 earnings per share for the current year.

Institutional Trading of Nuvectis Pharma

Several large investors have recently bought and sold shares of the business. Occam Crest Management LP grew its stake in Nuvectis Pharma by 31.0% during the 4th quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock valued at $2,869,000 after acquiring an additional 90,000 shares in the last quarter. Barclays PLC grew its stake in shares of Nuvectis Pharma by 31.3% in the 4th quarter. Barclays PLC now owns 24,185 shares of the company’s stock valued at $183,000 after buying an additional 5,760 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Nuvectis Pharma by 15.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock valued at $332,000 after buying an additional 6,040 shares during the period. State Street Corp grew its stake in shares of Nuvectis Pharma by 13.1% in the 4th quarter. State Street Corp now owns 154,666 shares of the company’s stock valued at $1,168,000 after buying an additional 17,950 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Nuvectis Pharma by 114.1% in the 4th quarter. Wells Fargo & Company MN now owns 16,929 shares of the company’s stock valued at $128,000 after buying an additional 9,022 shares during the period. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.